NCT06727617: Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors
- State
- Under way
- Phase
- Phase 2
- People
- 134 planned
- Started
- 19 Nov 2024
- Primary completion
- 31 Dec 2025
- Arms
- Serplulimab plus chemoradiotherapy group
- Results
- None posted
- 19 Nov 2024: Trial started
- 11 Dec 2024: Trial registered